Swine Vaccines - Global Strategic Business Report

The global market for Swine Vaccines was estimated at US$1.7 Billion in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Swine Vaccines market.

Global Swine Vaccines Market - Key Trends & Drivers Summarized

Why Are Vaccines Becoming Central to Modern Swine Herd Management?

The global swine industry is confronting mounting challenges ranging from emerging infectious diseases and biosecurity threats to growing pressure for antibiotic reduction. In this context, vaccines have evolved from a preventive option to a foundational component of herd health strategies. With disease outbreaks like African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever (CSF) causing devastating losses across major pork-producing regions, producers are increasingly leaning on vaccination protocols to mitigate risks and protect production continuity. Vaccines not only help control endemic diseases but also reduce the incidence of secondary infections, lowering the overall use of antimicrobials - a key goal in the global fight against antimicrobial resistance (AMR). Moreover, as pig farming scales up in intensity and density, the threat of rapid disease transmission grows, making routine immunization essential to minimize morbidity and mortality. As a result, vaccination is no longer seen as a cost but rather an investment in herd resilience, productivity, and long-term profitability, securing its place at the core of swine health management worldwide.

How Are New Vaccine Technologies Transforming Swine Disease Prevention?

Technological innovation is reshaping the development and delivery of swine vaccines, enabling faster, more effective, and more targeted immunization strategies. Advances in recombinant DNA technologies, viral vector platforms, and RNA-based vaccines are paving the way for next-generation solutions that offer broader protection with fewer side effects. Marker (DIVA) vaccines - those that differentiate infected from vaccinated animals - are gaining prominence, particularly for diseases with trade implications like CSF, as they support surveillance while maintaining disease-free certifications. Additionally, multivalent and combination vaccines are being developed to simplify vaccination schedules and reduce animal stress during administration. Intradermal and needle-free delivery systems are improving both animal welfare and biosecurity by minimizing tissue damage and cross-contamination risks. Diagnostic-linked vaccination (DLV) systems are also being piloted, integrating real-time disease diagnostics with vaccination decisions to improve timing and efficacy. These innovations are helping producers achieve higher immunity levels across herds, reduce labor time, and tailor vaccination programs to evolving disease pressures - marking a new era in data-driven, precision veterinary medicine.

What Role Do Regulations, Trade Dynamics, and Biosecurity Mandates Play?

The swine vaccines market is deeply influenced by regulatory frameworks, international trade conditions, and evolving biosecurity mandates. In many countries, vaccine use is closely regulated by government authorities such as the USDA, EMA, or CFDA, with strict approval pathways to ensure safety, efficacy, and compliance. As global pork trade continues to grow, especially between Asia, Europe, and the Americas, disease control becomes a prerequisite for export eligibility. Countries that can demonstrate effective vaccination programs and disease-free status have a significant advantage in maintaining market access and trade partnerships. This has pushed governments to fund mass vaccination campaigns, particularly for notifiable and transboundary diseases like ASF and Foot-and-Mouth Disease (FMD). Additionally, industry-driven certifications and retailer sourcing requirements are encouraging producers to maintain comprehensive vaccination records as part of animal welfare and sustainability commitments. Biosecurity has become a central tenet in swine farming, especially in light of recent outbreaks, and vaccines are now viewed as the first line of defense within integrated disease prevention protocols. The alignment of regulatory, trade, and farm-level expectations is reinforcing vaccine adoption as both a protective measure and a compliance requirement in modern swine production.

What’s Driving the Strong Growth in the Swine Vaccines Market?

The growth in the swine vaccines market is driven by a confluence of factors that span epidemiological trends, technological advancement, production system evolution, and global policy alignment. The rising prevalence of infectious and emerging diseases - such as PRRS, Mycoplasma hyopneumoniae, and ASF - is creating sustained demand for both prophylactic and emergency-use vaccines. Technological progress in adjuvant formulations, antigen discovery, and vaccine delivery is broadening product availability and effectiveness, opening up new segments for innovation. The global shift away from antibiotics - driven by regulatory bans, export standards, and consumer awareness - is amplifying the importance of vaccines as a primary disease control strategy. At the production level, intensification of swine farming and the consolidation of large-scale operations are increasing the economic value of herd health management, with vaccines playing a central role in risk mitigation. In parallel, public-private partnerships and government-funded immunization initiatives in Asia, Latin America, and Africa are supporting vaccine deployment in both commercial and smallholder systems. Improved cold chain logistics, the rise of veterinary health informatics, and the integration of vaccination into precision livestock farming platforms are further enhancing accessibility and impact. Together, these drivers are propelling the swine vaccines market forward - solidifying its position as a critical pillar of sustainable, scalable, and biosecure pork production worldwide.

Report Scope

The report analyzes the Swine Vaccines market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product (Inactivated, Modified/Attenuated Live, Others); Disease Type (Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others); Administration Route (Injectables, Intranasal, Oral)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Inactivated segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 4.1%. The Modified / Attenuated Live segment is also set to grow at 2.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $462.6 Million in 2024, and China, forecasted to grow at an impressive 6.9% CAGR to reach $424.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Swine Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Swine Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Swine Vaccines Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aptimmune Biologics, Baseimmune, Biogenesis Bago, Boehringer Ingelheim International GmbH, Cambridge Technologies and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

• Aptimmune Biologics
• Baseimmune
• Biogenesis Bago
• Boehringer Ingelheim International GmbH
• Cambridge Technologies
• Ceva Santé Animale
• Codagenix
• Elanco Animal Health Incorporated
• Genvax Technologies
• HIPRA
• Indian Immunologicals Limited
• iBio
• KM Biologics
• Merck & Co., Inc.
• Phibro Animal Health Corporation
• Ring Biotechnology Co Ltd.
• Sequent Scientific Limited
• Serum Institute of India
• Vaxxinova International BV
• Vetoquinol S.A.
• Virbac
• ViroVet

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry